Erasca (ERAS) Return on Capital Employed (2021 - 2026)
Erasca posted quarterly Return on Capital Employed of 72.93% for Q1 2026, down 3470.0% year-on-year from 2.16% in Q1 2025, and down 96.55% on a QoQ basis from 37.1% in Q4 2025.
Erasca (ERAS) has 6 years of Return on Capital Employed data on file, last reported at 72.93% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3470.0% year-over-year to 72.93%; the trailing twelve-month figure through Mar 2026 stood at 72.93% (down 3470.0% YoY), and the FY2025 full-year result was 33.48%, up 953.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 72.93%, down from 37.1% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.36% in Q1 2022 and bottomed at 72.93% in Q1 2026.
- The 5-year median for Return on Capital Employed is 37.13% (2023), against an average of 43.36%.
- The widest annual swing landed in 2024, when Return on Capital Employed jumped 2519 bps; it then tumbled 3470 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 57.28% in 2022, then soared by 35 bps to 37.13% in 2023, then gained by 0 bps to 37.08% in 2024, then retreated by 0 bps to 37.1% in 2025, then plunged by 97 bps to 72.93% in 2026.
- The last three Return on Capital Employed figures came in at 72.93% (Q1 2026), 37.1% (Q4 2025), and 35.63% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -72.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.93% |
| Dec 31, 2025 | -37.10% |
| Sep 30, 2025 | -35.63% |
| Jun 30, 2025 | -34.11% |
| Mar 31, 2025 | -38.22% |
| Dec 31, 2024 | -37.08% |
| Sep 30, 2024 | -35.74% |
| Jun 30, 2024 | -41.41% |
| Mar 31, 2024 | -40.68% |
| Dec 31, 2023 | -37.13% |
| Sep 30, 2023 | -60.93% |
| Jun 30, 2023 | -57.57% |
| Mar 31, 2023 | -53.25% |
| Dec 31, 2022 | -57.28% |
| Sep 30, 2022 | -33.60% |
| Jun 30, 2022 | -34.15% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -25.72% |
| Sep 30, 2021 | -46.40% |